Диссертация (1140465), страница 23

Просмтор этого файла доступен только зарегистрированным пользователям. Но у нас супер быстрая регистрация: достаточно только электронной почты!

Текст из файла (страница 23)

Mandrekar, A. Ambade, A. Lim, et al. // Hepatology. – 2017.– Open access.108. 4-Hydroxynonenal as a selective profibrogenic stimulus for activatedhuman hepatic stellate cells [Text] / E. Zamara, E. Novo, F. Marra, et al. // J. Hepatol. – 2004.

– Vol. 40. – P. 60-68.109. The role of reactive oxygen species in integrin and matrix metalloproteinase expression and function [Text] / G. Svineng, C. Ravuri, O. Rikardsen, et al.// Connect.Tissue Res. – 2008. – Vol. 49. – P. 197-202.110. Cohen, J.I. Pathogenesis of alcoholic liver disease: interactions betweenparenchymal and non-parenchymal cells [Text] / J.I. Cohen, L.E. Nagy // J.Dig.Dis. – 2011. – Vol. 12. – P. 3-9.111.

Rushmore, T.HB. The antioxidant responsive element. Activation byoxidative stress and identification of the DNA consensus sequence required forfunctional activity [Text] / T.H. Rushmore, M.R. Morton, C.B.Pickett // J. Biol.Chem. – 1991. – Vol. 266. – P. 11632-11639.136112. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements [Text] / K.

Itoh, T.Chiba, S. Takahashi, et al. // Biochem.Biophys. Res. Commun. – 1997. – Vol. 236.– P. 313-322.113. Generation of superoxide from reaction of 3H-1,2-dithiole-3-thionewith thiols: implications for dithiolethione chemoprotection [Text] / Z. Jia, H. Zhu,M.A.

Trush, et al. // Mol. Cell.Biochem.– 2008. – Vol. 307. – P. 185-191.114. Maher, J. The rise of antioxidant signaling – the evolution and hormeticactions of Nrf2 [Text] / J. Maher, M. Yamamoto // Toxicol. Appl. Pharmacol. –2010. – Vol. 244. – P. 4-15.115. Nuclear factor E2-related factor 2-dependent myocardiac cytoprotectionagainst oxidative and electrophilic stress [Text] / H.

Zhu, Z. Jia, B.R. Misra, et al.// Cardiovasc.Toxicol.– 2008. – Vol. 8. – P. 71-85.116. Yeligar, S.M. Ethanol-induced HO-1 and NQO1 are differentially regulated by HIF-1alpha and Nrf2 to attenuate inflammatory cytokine expression[Text] / S.M. Yeligar, K. Machida, V.K.Kalra // J. Biol. Chem. – 2010. – Vol. 285.– P. 35359-35373.117.

Gong, P. Nrf2 is increased by CYP2E1 in rodent liver and HepG2 cellsand protects against oxidative stress caused by CYP2E1 [Text] / P. Gong, A.I.Cederbaum //Hepatology. – 2006. – Vol. 43. – P. 144-153.118. Histopathological diagnosis of non-alcoholic and alcoholic fatty liverdisease [Text] / A. Tannapfel, H. Denk, H.P. Dienes, et al. //Virchows Arch.–2011. – Vol.458. – P. 511-523DOI: 10.1007/ s00428-011-1066-1
119. Yip, W.W. Alcoholic liver disease [Text] / W.W. Yip, A.D.

Burt //Semin.Diagn.Pathol.– 2006. – Vol.23. – P. 149-160 
120. Crawford, J.M. Histologic findings in alcoholic liver disease [Text] /J.M. Crawford //Clin.Liver Dis.– 2012. – Vol.16. – P. 699-716 DOI:10.1016/j.cld.2012.08.004
137121. Sachuja, P. Pathology of alcoholic liver disease, can it be differen- tiated from nonalcoholic steatohepatitis? [Text] / P.

Sakhuja // World J. Gastroenterol.– 2014. – Vol. 20, No. 44. – P. 16474-16479.122. Feldstein, A.E. Apoptosis in alcoholic and nonalcoholic steatohepatitis[Text] / A.E. Feldstein, G.J.Gores //Front Biosci.– 2005. – Vol.10. – P. 3093-3099.123. Denk, H.

Mallory bodies revisited [Text] / H. Denk, C. Stumptner, K.Zatloukal //J. Hepatol.– 2000. – Vol.32. – P. 689-702.
124. Lefkowitch, J.H. Morphology of alcoholic liver disease [Text] / J.H.Lefkowitch //Clin.Liver Dis.– 2005. – Vol.9. – P. 37-53.
125. Yeh, M.M. Pathology of nonalcoholic fatty liver disease [Text] / M.M.Yeh, E.M. Brunt // Am. J. Clin.Pathol.– 2007.

– Vol.128. – P. 837-847.
126. Tiniakos, D.G. Liver biopsy in alcoholic and non-alcoholic steatohepatitis patients [Text] / D.G. Tiniakos //Gastroenterol.Clin.Biol.– 2009. – Vol.33. – P.
930-939. DOI: 10.1016/j.gcb.2009.05.009] 
127. Theise, N.D. Histopathology of alcoholic liver disease [Text] / N.D.Theise //Clin.Liver Dis.– 2013. – Vol.2. – P.

64-67. DOI: 10.1002/cld.172128. Alcoholic hepatitis. Natural history and evaluation of prednisolonetherapy [Text] / R.A. Helman, M.H. Temko, S.W. Nye,et al. // Ann. Intern.Med.–1971. – Vol. 74. – P. 311-321. 
129.Corticosteroid therapy of alcoholic hepatitis [Text] / W.C.

Maddrey,J.K. Boitnott, M.S. Bedine,et al. // Gastroenterology. – 1978. – Vol. 75. – P. 193199.130. Adrenocorticosteroid therapy
in alcoholic hepatitis. A prospective,double-blind randomized study [Text] / B.L. Blitzer, M.G. Mutchnick, P.H. Joshiet al. // Am.
J. Dig.Dis.– 1977. – Vol. 22. – P. 477-484. 
131. Lesesne, H.R. Treatment of alcoholic hepatitis 
with encephalopathy.Comparison of prednisolone with caloric supplements [Text] / H.R. Lesesne, E.M.Bozymski, H.J.

Fallon // Gastroenterology. – 1978. – Vol. 74. – P. 169-173. 
138132. A controlled trial of
6-methylprednisolone in acute alcoholic hepatitis.With a note on published results in encephalopathic patients [Text] / J.B. Shumaker, R.H. Resnick, J.T. Galambos et al. // Am. J. Gastroenterol.– 1978. – Vol. 69. –P.

443-449. 
133. Double-blind controlled trial of prednisolone therapy in patients withsevere acute alcoholic hepatitis and spontaneous encephalopathy [Text] / W. Depew, T. Boyer, M. Omata et al. //Gastroenterology.– 1980. – Vol. 78. – P. 524-529.134. Teodossi, A. Controlled trial of methylprednisolone therapy in severeacute alcoholic hepatitis [Text] / A. Teodossi, A.L. Eddleston, R. Williams // Gut.– 1982.

– Vol. 23. – P. 75-79. 
135. Methylprednisolone therapy 
in patients with severe alcoholic hepatitis.A randomized multicenter trial [Text] / R.L. Carithers Jr., H.F. Herlong, A.M.Diehl et al. //
Ann. Intern.Med.– 1989. – Vol. 110. – P. 685-690. 
136. A randomized trial of prednisolone
in patients with severe alcoholichepatitis [Text] / M.J. Ramond, T. Poynard, B. Rue et al. // N. Engl. J.

Med.– 1992.– Vol. 326. – P. 507-512. 
137. Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial [Text] / E.Cabre, P. Rodriguez-Iglesias, J. Caballeria et al.

// Hepatology.– 2000. – Vol. 32. –P. 36-42.138. Antioxidants versus corticosteroids in the treatment of severe alcoholichepatitis – a randomised clinical
trial [Text] / M. Phillips, H. Curtis, B. Portmannet al. // J. Hepatol.– 2006. – P. 44. – P. 784-790. 
139. Prednisone therapy of
acute alcoholic hepatitis. Report of a controlledtrial [Text] / J.L. Campra, E.M. Hamlin Jr., R.J. Kirshbaum et al.

// Ann. Intern.Med.– 1973. – Vol. 79. – P. 625-631. 
140. Prednisolone or pentoxifylline for alcoholic hepatitis [Text] / M.R.Thursz, P. Richardson, M. Allison et al. // N. Engl. J. Med.– 2015. – Vol. 372. – P.1619-1628.139141. Short-term and long-term survival in patients with alcoholic hepatitistreated with oxandrolone and prednisolone [Text] / C.L. Mendenhall, S. Anderson,P. Garcia-Pont et al. // N. Engl. J. Med.– 1984. – Vol.

311. – P. 1464-1470.142. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data [Text] / P. Mathurin, J.O'Grady, R.L. Carithers et al. // Gut. – 2011. – Vol. 60. – P. 255-260.143. Treatment of alcoholic liver disease [Text] / A. Barve, R. Khan, L.Marsano, et al. // Ann. Hepatol. – 2008. – Vol. 7, No. 1. – P. 5-15.144. MELD accurately predicts mortality in patients with alcoholic hepatitis[Text] / W. Dunn, L.H. Jamil, L.S. Brown et al.

// Hepatology. – 2005. – Vol. 41. –P. 353-358.145. A day-4 Lille model predicts response to corticosteroids and mortalityin severe alcoholic hepatitis [Text] / M. Garcia-Saenz-de-Sicilia, C. Duvoor, J. Altamirano et al. // Am. J. Gastroenterol.– 2016. – Open Access.146. Management practices of hepatitis C virus infected alcoholic hepatitispatients: A survey of physicians [Text] / A.K. Singal, H. Salameh, A. Singal et al.// World J. Gastrointest.Pharmacol.– 2013. – Vol.

4. – P. 16-22.147. Ahn, J.M.T. Evaluation and management of alcoholic hepatitis: A survey of current practices [Text] / J.M.T. Ahn, S.M. Cohen // Hepatology.– 2009. –Vol. 612A.148. Alcoholic hepatitis: current challenges and future directions [Text] /A.K.

Singal, P.S. Kamath, G.J. Gores et al. // Clin.Gastroenterol.Hepatol.– 2014. –Vol. 12. – P. 555-564.149. Sanyal, A.J. Gaps in knowledge and research priorities for alcoholichepatitis [Text] / A.J. Sanyal, B. Gao, G. Szabo // Gastroenterology.– 2015. – Vol.149. – P. 4-9.150. Bioenergetic Health Index: a new concept in mitochondrial translationalresearch [Text] / B.K. Chacko, P.A. Kramer, S.

Ravi et al. // Clin.Sci. (Lond.). –2014. – Vol. 127. – P. 367-373.140151. Corticosteroids and pentoxifylline for the treatment of alcoholic hepatitis: current status [Text] / A.K. Singal, I. Walia, A. Singal et al. // World J. Hepatol.– 2011. – Vol. 3. – P. 205-210.152. Impact of hepatitis C virus infection on the course and outcome of patients with acute alcoholic hepatitis [Text] / A.K. Singal, S. Sagi, Y.F. Kuo et al. //Eur. J. Gastroenterol.Hepatol.– 2011. – Vol. 23. – P.

204-209.153. Punzalan, C.S. Alcoholic hepatitis and HCV interactions in the modulation of liver disease [Text] / C.S. Punzalan, T.N. Bukong, G. Szabo // J. Viral.Hepat.– 2015. – Vol. 22. – P. 769-776.154. Shoreibah, M. Alcoholic hepatitis and concomitant hepatitis C virus infection [Text] / M. Shoreibah, B.S. Anand, A.K.Singal // World J. Gastroenterol.–2014. – Vol. 20. – P. 11929-11934.155. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor [Text] / A.

Louvet, F. Wartel, H.Castel et al. // Gastroenterology. – 2009. – Vol. 137. – P. 541-548.156. Franchimont, D. Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppressionfor new treatment strategies [Text] / D.

Franchimont // Ann. N. Y. Acad. Sci.–2004. – Vol. 1024. – P. 124-137.157. Corticosteroids and occurrence of and mortality from infections in severe alcoholic hepatitis: a meta-analysis of randomized trials [Text] / B.S. Hmoud,K. Patel, R. Bataller et al. // Liver Int.– 2015. – Vol. 36. – P. 721-728.158. In patients with severe alcoholic hepatitis, prednisolone increases susceptibility to infection and infection-related mortality, and is associated with highcirculating levels of bacterial DNA [Text] / N. Vergis, S.R.

Atkinson, S. Knapp etal. // Gastroenterology. – 2017. – Vol. 152. – P. 1068-1077 e4.159. Reuter, B.K. Phosphodiesterase inhibitors prevent NSAID enteropathyindependently of effects on TNF-alpha release [Text] / B.K. Reuter, JL. Wallace //Am. J. Physiol.– 1999. – Vol. 277. – G847-G854.141160. McClain, C.J. Increased tumor necrosis factor production by monocytesin alcoholic hepatitis [Text] / C.J. McClain, D.A. Cohen // Hepatology.– 1989. –Vol. 9. – P. 349-351.161. Pentoxifylline improves short-term survival in severe acute alcoholichepatitis: a double-blind, placebo-controlled trial [Text] / E.

Akriviadis, R. Botla,W. Briggs et al. // Gastroenterology.– 2000. – Vol. 119. – P. 1637-1648.162. Role of pentoxifylline in treatment of severe alcoholic hepatitis – a randomized controlled trial [Text] / H. Paladugu, P. Spinelli, L. Dalvi et al.// J. Gastroenterol.Hepatol.– 2006. – Vol. 21. – P. 1-10.163. Pentoxifylline may prevent renal impairment (hepatorenal syndrome) insevere acute alcoholic hepatitis [Text] / J.G. McHutchison, R.

Характеристики

Список файлов диссертации